A previous study also reported that bevacizumab in addition to EGFR-TKIs was more effective for brain metastasis control and prevention of the progression of brain metastasis than EGFR-TKI treatment alone in NSCLC with EGFR mutations (35). This evidence concerns the gene EGFR and non-small cell lung carcinoma.